Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. filed a shelf registration to offer up to $300,000,000 of securities. The shelf prospectus registers a mix of Common Stock, Preferred Stock, Debt Securities, Warrants, Rights and Units for sale from time to time. The prospectus is a general description; each offering will be described in a prospectus supplement that will state the specific terms, price and net proceeds.
The document discloses clinical-stage operations focused on brain-localized malignancies and two lead product candidates, NEO100 (intranasal) and NEO212 (oral and planned intranasal development). It reports total revenue of $122,990 for 2023–2025, a net loss of $62,146,210 in 2025, and an accumulated deficit of $112,754,655 as of December 31, 2025.
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company developing therapies for aggressive brain cancers using novel delivery methods to overcome the blood-brain barrier. Its lead intranasal candidate NEO100 targets IDH-mutant high-grade gliomas and has Orphan Drug Designation for malignant glioma.
Across Phase I/IIa and compassionate-use settings, intranasal NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma showed radiographic responses in 24% of 25 patients, PFS-6 of 44% and 36% survival at 18 months, with generally favorable tolerability. Oral conjugate NEO212 has completed Phase 1 dose escalation, establishing a 610 mg recommended Phase 2 dose in recurrent CNS malignancies.
The company expanded its platform in 2025 by acquiring an AI-driven drug discovery and quantum modeling portfolio, including U.S. Patent No. 11,788,057 B2, for approximately $3.5 million, to support ultrasound-responsive CNS therapies and 3D bioprinted tumor organoids. It holds an extensive global patent estate licensed from USC and reports 23,806,216 common shares outstanding and non-affiliate equity market value of about $67.9 million.
NeOnc Technologies Holdings, Inc. entered a third Securities Purchase Agreement on March 20, 2026 as part of a broader private financing program. This agreement covers up to 545,583 shares of common stock at $7.20 per share and five-year warrants to buy up to 545,583 shares at $9.00 per share. The initial closing on March 20, 2026 provided 138,889 shares and 138,889 warrants to one investor for $1,000,000. The company plans to use the net proceeds for working capital and relied on a private offering exemption under Section 4(a)(2) of the Securities Act, with a commitment to later file a resale registration statement for the shares and warrant shares.
NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer, effective March 12, 2026. The company entered into an employment agreement providing a $162,500 annual base salary and a grant of 170,000 restricted shares under the 2023 Equity Incentive Plan.
Of these restricted shares, 53,333 vested on March 12, 2026, 58,333 will vest on the one-year employment anniversary, and 58,334 are performance-based, vesting upon achievement of specified metrics in his grant agreement. Choi, a CPA with over a decade of public-company accounting and controls experience, will lead accounting, financial reporting, internal controls, and governance as NeOnc advances its CNS cancer drug programs.
NeOnc Technologies Holdings, Inc. furnished an update on its oral brain cancer drug candidate NEO212, sharing full Phase 1 dose-escalation results and outlining next development steps. The Phase 1/2 trial reached Maximum Tolerated Dose at 810 mg in Cohort 5, and the Recommended Phase 2 Dose was set at 610 mg (Cohort 4), with 400 mg as the starting dose for the Phase 2a metastasis cohort.
Although Phase 1 was primarily a safety study, NeOnc reported early signs of anti-tumor activity, including durable disease control in heavily pretreated glioblastoma and brain metastasis patients. Across cohorts, the company highlighted low levels of systemic NEO212 metabolites and reported no clinically meaningful myelosuppression, hepatic, or renal toxicity, which are common concerns with standard temozolomide therapy.
NeOnc plans to move NEO212 into Phase 2 expansion cohorts focused on recurrent central nervous system cancers and intends to request a Type B (End-of-Phase 1) FDA meeting to discuss safety, pharmacology, preliminary efficacy, Phase 2 design, and a potential accelerated approval pathway.
NeOnc Technologies Holdings, Inc. disclosed that its wholly owned subsidiary NeOnc Technologies, Inc. has fully settled a contract dispute with Fox Infused, LLC. The dispute arose after NeOnc terminated a July 1, 2022 Intellectual Property License and Supply Agreement on April 25, 2023, which led to litigation and then arbitration. The parties had agreed to settle for a $600,000 payment tied to the company’s initial public offering or March 31, 2024. On February 27, 2026, NeOnc paid Fox Infused $737,920.77, including $137,920.77 in interest, and the matter is now fully resolved.
NeOnc Technologies Holdings, Inc. entered into a series of private financing deals to sell common stock and warrants to institutional and other investors. An earlier Securities Purchase Agreement allowed issuance of up to 2,222,222 shares at $7.20 per share and five-year warrants exercisable at $9.00 per share.
Under that agreement, the company first issued 1,388,888 shares and matching warrants to a single institutional investor for $10 million, then 86,361 shares and matching warrants to three investors for $621,804.11. A new Securities Purchase Agreement dated February 24, 2026 covers up to 746,973 additional shares and warrants on the same terms, with an initial closing of 201,390 shares and matching warrants to four investors for $1,450,004. NeOnc plans to use the net proceeds for working capital and will later file a resale registration statement for the shares and warrant shares.
NeOnc Technologies Holdings, Inc. is planning an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific / 9:00 a.m. Eastern Time. The company will present initial data from the Phase 1 dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial.
Management and independent members of NeOnc’s Scientific Advisory Board will discuss safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps for NEO212, an oral bioconjugated temozolomide (TMZ) platform for central nervous system malignancies.
NeOnc Technologies Holdings, Inc. is registering up to 2,950,498 shares of common stock for resale by existing investors, including 1,475,249 outstanding shares and 1,475,249 shares issuable upon warrant exercise. The company is not selling shares itself and will only receive cash if the warrants, exercisable at $9.00 for five years, are exercised for cash, which would be used for general corporate purposes.
Shares outstanding were 22,692,159 as of January 29, 2026 and would be 24,167,408 if all warrants are exercised. NeOnc is a clinical‑stage biopharmaceutical company developing intranasal and oral therapies for aggressive brain cancers, led by NEO100 and NEO212. It reported minimal revenue, large recurring net losses (including a $46.6 million loss for the nine months ended September 30, 2025) and has substantial doubt about its ability to continue as a going concern.